Celmatix Selected to Receive $3.5 Million Award from ARPA-H’s Sprint for Women’s Health

Celmatix Inc. has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an awardee of the Sprint for Women’s Health, to address critical unmet challenges in women’s health, champion transformative innovations, and tackle health conditions that uniquely or disproportionately affect women. Celmatix will receive $3.5 million in funding over two years through the Sprint for Women’s Health spark track for early-stage research efforts.

Read more here

Previous
Previous

Celmatix Launches Novel Endometriosis Drug Program

Next
Next

Celmatix Nominates First Lead Compound in Oral Fertility Drug Program